|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preoperative serum PSA concentration did not correlate with tumor grade or ploidy status, but on multivariate analysis, when paired with ploidy status, independently contributed to the propensity for ECS, metastasis, and disease recurrence.
|
7954242 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Unlike Ad-sPSA-E1, an adenoviral vector with viral replication controlled by a strong super prostate-specific antigen (sPSA) promoter which only replicates in PSA-expressing cells with androgen receptor (AR), Ad-hOC-E1 retarded the growth of both androgen-dependent and androgen-independent prostate cancer cells irrespective of their basal level of AR and PSA expression.A single i.v. administration of 2 x 10(9) plaque-forming units of Ad-hOC-E1 inhibited the growth of previously established s.c. DU145 tumors (an AR- and PSA-negative cell line).
|
12036918 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA immunoreactivity in the lung tissue was localized by immunohistochemistry to normal epithelial cells adjacent to the tumor which was completely negative for PSA.
|
9815800 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The grouping was applied according to the clinical routine laboratory parameters (vitamin D<sub>3</sub>) and the tumor markers (PSA, fPFA).
|
29886377 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, tumor growth inhibition and PSA decrease trends were greater with VT-464 than with AA.
|
25351916 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Two novel patient-derived PCa xenograft models from high grade PCa specimens were established by implanting the specimens into nude mice and passing tumor pieces through subcutaneous injection in nude mice, and then treated with kava extract and flavokawain B to examine their effects on tumor growth, AR expression and serum PSA levels.
|
22347450 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant decrease in tumor volume and PSA levels was observed when edelfosine and AD were combined, compared with edelfosine alone.
|
26944919 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA/MC-38 tumors grew more rapidly in athymic mice than in syngeneic C57BL/6 mice, and in both mouse strains, the PSA/MC-38 tumors grew more slowly than control vector-transduced tumors.
|
7538903 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA in tumor tissue was characterized by two immunoassays, HPLC, immunohistochemistry, reverse transcription-PCR, Southern blotting, and DNA sequencing.
|
7536128 |
1995 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Inter-racial difference in SUVmax of the primary tumor as well as its correlation with serum PSA were also determined.
|
29101444 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High EZH2 expression was strongly associated with high Gleason grade (P < 0.0001), advanced pathological tumor stage (P < 0.0001), positive nodal status (P < 0.0001), elevated preoperative PSA level (P = 0.0066), early PSA recurrence (P < 0.0001) and increased cell proliferation P < 0.0001).
|
26392259 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High AMACR showed marginal association with PSA biochemical recurrence (BCR) (p = 0.06) which was slightly more pronounced in ERG-positive tumors (p = 0.04).
|
27271990 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High PSA mRNA was found more frequently in PC patients with poorly differentiated (23.1%) than in those with well (4.5%) or moderately (4.3%) differentiated tumors.
|
16516186 |
2006 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest that CYP1B1 and PSA variants may affect the risk of prostate cancer and tumor aggressiveness.
|
16172228 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PCA3 gene expression discriminates LN metastasis and might outperform PSA gene activity in reflecting tumor cell burden in pelvic LNs of PCa patients.
|
25769446 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Decreased CD147 expression was significantly linked to high preoperative PSA values, high Gleason grade, advanced tumor stage (p<0.0001 each), and positive lymph node involvement (p=0.0026) in all cancers.
|
23948277 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The survival time predictions using the current clinical parameters only, such as age at diagnosis, Gleason score, PSA value and tumor stage, and clinical parameters supplemented with the expression levels of IGFBP3 and F3, were compared.
|
26731648 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, PROS1 knockdown reduced anchorage-independent growth in-vitro, reduced tumor xenograft growth in nude mice and altered their differentiation profile.
|
28118606 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Down-regulation of SOX9 expression was particularly strongly associated with PSA recurrence in ERG-positive tumors harboring PTEN deletions (p=0.001), but had no significant effect in ERG-negative cancers or in tumors with normal PTEN copy numbers.
|
26030748 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumour-Secreted Protein S (ProS1) Activates a Tyro3-Erk Signalling Axis and Protects Cancer Cells from Apoptosis.
|
31766614 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer.
|
30592769 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytotoxicity was evidenced by transient rise in PSA and tumor histology.
|
24052127 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tissue kallikrein, the oldest member and kinin-releasing enzyme, and KLK3/PSA, a tumor biomarker for prostate cancer are the most prominent components of the family.
|
29885274 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Step-wise logistic regression analysis was used to identify predictive parameters of advanced disease and it was observed that the DD genotype (p = 0.002, OR = 5.4, 95% CI = 1.84-16.06), high-grade tumour (p < 0.001, OR = 8.04, 95% CI = 3.03-21.33), and high serum PSA (p < 0.001, OR = 10.87, 95% CI = 4.06-29.13) were significantly associated with advanced disease.
|
14991898 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor volume and serum PSA (LNCaP only) were measured and intracellular pH was determined, using magnetic resonance spectroscopy (MRS), at tumor and leg muscle sites.
|
15754319 |
2005 |